Barclays raised the firm’s price target on Quest Diagnostics (DGX) to $190 from $185 and keeps an Equal Weight rating on the shares as part of a Q3 preview for the life science tools and diagnostics group. The firm views the companies’ end markets as stable with improvements likely going forward. In addition, investment sentiment “feels bottomed” as share valuations have come down, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Guardant Health, Quest Diagnostics announce blood-based screening test pact
- Quest Diagnostics partners with Epic for streamlined laboratory testing
- Haystack Oncology, Rutgers Cancer Institute collaborate to study Haystack MRD
- Quest Diagnostics: Strong Growth Prospects and Operational Efficiency Justify Buy Rating
- Quest Diagnostics launches advanced pharmacogenomics offering